Investor sentiment has fundamentally changed. During the COVID era, investors funded good ideas. Now, they want to de-risk their investments as much as possible, often requiring solid Phase 1 and even compelling Phase 2 data before committing significant capital.

Contrary to seeking fully de-risked assets, pharmaceutical companies often prefer acquiring companies with some remaining clinical risk. This strategy allows them to leverage unique insights on early data to acquire assets at a better valuation, creating an opportunity for outsized returns before the value is obvious to others.

A cultural divide exists in biotech investing. East Coast VCs, rooted in a traditional biotech ecosystem, are more skeptical of AI and demand hard biological data. West Coast VCs, surrounded by tech innovation, are more comfortable backing the promise of AI platforms before seeing extensive wet lab validation.

Investors without a scientific background can de-risk biotech portfolios by avoiding early-stage "science projects" (Phase 1-2). Instead, they should focus on companies that have completed Phase 3 trials. This strategy shifts the primary risk from unpredictable scientific development to more analyzable commercial execution.

The fundamental risk profile shifts dramatically between venture stages. Early-stage investors bet against business failure, an idiosyncratic risk unique to each company. Late-stage investors are primarily betting on public market multiples and macro sentiment holding up—a systematic risk affecting all late-stage assets simultaneously.

As CFIUS reviews increasingly complicate US venture investment in Chinese companies, investors are seeking alternatives. South Korea is emerging as a key "CFIUS-safe" location, offering access to high-quality, early-stage healthcare assets without the geopolitical and regulatory risks associated with investing in China.

In stark contrast to the US, Chinese investors are accelerating funding for early-stage cell and gene therapies, which now account for 29% of seed/Series A rounds. These firms are specifically backing technologies like NK cell therapies, which have fallen out of favor in the West, creating a divergent global innovation strategy.

Big Pharma's strategy differs by region: they are willing to acquire innovative US biotechs outright but prefer to only license assets from Chinese companies. This is because Chinese assets can be secured at significantly lower valuations without the complexities of a full M&A transaction, creating an exit dilemma for VCs in China.

Through massive government investment in biotech infrastructure, China has become the global hub for early-stage clinical drug development. Both Chinese and Western companies now conduct initial human trials there to move much faster and at a significantly lower cost, giving China a strategic foothold in the pharma value chain.